UK competition watchdog accuses Merck of obstructing biosimilars

LONDON (Reuters) - Britain's competition watchdog on Tuesday accused Merck& Co of operating an anti-competitive discount scheme for its medicine Remicade, designed to restrict competition from so-called biosimilar copies of the drug.

Source: Reuters: Health - May 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news